Investigational Drug Information for Hematoporphyrin
✉ Email this page to a colleague
What is the drug development status for Hematoporphyrin?
Hematoporphyrin is an investigational drug.
There have been 9 clinical trials for Hematoporphyrin.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2005.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Mesothelioma. The leading clinical trial sponsors are Roswell Park Cancer Institute, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
Summary for Hematoporphyrin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,803 |
| WIPO Patent Applications | 1,592 |
| Japanese Patent Applications | 50 |
| Clinical Trial Progress | Phase 3 (2005-03-01) |
| Vendors | 31 |
Recent Clinical Trials for Hematoporphyrin
| Title | Sponsor | Phase |
|---|---|---|
| An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | Second Affiliated Hospital of Guangzhou Medical University | N/A |
| Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | Roswell Park Cancer Institute | Phase 1 |
| Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Hematoporphyrin
Top disease conditions for Hematoporphyrin
Top clinical trial sponsors for Hematoporphyrin
US Patents for Hematoporphyrin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
